GlassScriptPhysician profile
Rachna Arora
NPI 1114187200
$69,469.66
in general payments reported to CMS, 2019-2025
18 companies · $4,285 in 2025
The $4,285 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,717 · 2021: $15K · 2022: $9,784 · 2023: $5,698 · 2024: $21K · 2025: $4,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $1,427 · Travel and Lodging: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,062.50 |
| Food and Beverage | $1,426.64 |
| Travel and Lodging | $1,056.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36,895.88 | 2020-2024 | Linzess, Viberzi, Creon |
| Phathom Pharmaceuticals, INC. | $21,099.31 | 2024-2025 | Voquezna |
| Allergan, INC. | $9,444.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.75 | 2019-2023 | Trulance |
| Baxter Healthcare | $290.00 | 2019 | |
| Ambu A/S | $200.00 | 2021 | |
| Genzyme Corporation | $185.00 | 2019 | |
| Janssen Biotech, INC. | $180.53 | 2019-2024 | Stelara, Tremfya |
| Mauna Kea Technologies, INC. | $171.60 | 2019-2022 | |
| Covidien LP | $121.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.55 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $85.62 | 2019-2020 | |
| Csl Behring | $83.34 | 2019 | |
| Pfizer INC. | $59.55 | 2019-2024 | |
| Endogastric Solutions, INC | $52.74 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $41.57 | 2019 | |
| Braintree Laboratories, INC. | $37.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $37.60 | 2023-2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachna Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.